Risk assessment of venous thromboembolism in inflammatory bowel disease by inherited risk in a population-based incident cohort

Figure 1 Kaplan-Meier analysis. A and B: Kaplan-Meier analysis for time to incident venous thromboembolism in the UK Biobank during the entire follow-up period for inflammatory bowel disease (IBD) patients (A) and cancer patients (B); C and D: Within the 3 years after IBD diagnosis for IBD patients (C) and cancer patients (D). IBD: Inflammatory bowel disease.

Figure 2 Proportion of incident venous thromboembolism in the UK Biobank by carrier status of F5 factor V leiden and/or F2 prothrombin gene mutation, decile of polygenic score_nonF5/F2, and decile of original polygenic score. Dot and vertical line indicate mean and 95% confidence interval, respectively. A: Carrier status of F5 factor V leiden and/or F2 prothrombin gene mutation; B: Decile of polygenic score (PGS)_nonF5/F2; C: Decile of original PGS. Dot and vertical line indicate mean and 95% confidence interval, respectively. VTE: Venous thromboembolism.